Minoxidil vs Peptide-Based Hair Loss Treatment: Which Wins Long-Term?

There is a study that circulates endlessly on hair loss forums. It found that a combination of Redensyl, Capixyl, and Procapil outperformed 5% Minoxidil in a 24-week randomised controlled trial. That number gets screenshotted, shared, and used to sell peptide serums across Pakistan without anyone explaining what the study actually measured, who conducted it, or what it did not compare. This article does that job properly.

By Radiance360 · Pharmacist-Formulated · 2026

What this article covers

The Karaca and Akpolat 2019 RCT explained honestly, including its real findings and its limitations. How Minoxidil and peptide actives work through different biological mechanisms. Why long-term results depend on more than a 24-week trial. Where Regrow Xpert Actives 20% and the Xtra Hair range each fit in a treatment plan built to last years, not months.

The Study Everyone Cites, and What It Actually Found

In 2019, Turkish researchers Karaca and Akpolat published a randomised controlled trial in the Journal of Cosmetology and Trichology. They recruited 106 adult men with androgenetic alopecia and split them into two groups: one applied 5% Minoxidil twice daily, the other applied a combination of Redensyl, Capixyl, and Procapil (RCP) twice daily. Both groups continued for 24 weeks.

The results that circulate online: RCP group scored 64.7% on researcher evaluation. Minoxidil group scored 25.5%. Global photographic evaluation also favoured RCP at 88.9% versus 60%.

Those numbers are real. The study is real. What matters is what they measured.

The primary endpoints were subjective: researcher evaluation scores based on visual assessment, and global photograph comparisons rated by the investigators. The study did not measure objective hair counts using standardised trichoscopy. It did not use phototrichogram analysis. It did not measure hair shaft diameter. These are the endpoints that clinical dermatology considers most reliable for quantifying actual hair density change. Instead, the 2019 RCT used the kind of assessment that is most susceptible to observer bias and placebo effect.

A second critical limitation: the study compared RCP against 5% Minoxidil alone, with no Finasteride. It did not compare RCP against the current standard of care, which is Minoxidil combined with a DHT blocker. Comparing a peptide complex against pharmaceutical monotherapy is not the same as comparing it against combination therapy.

This does not mean the study was dishonest or that RCP does not work. It means the widely shared 64.7% vs 25.5% comparison needs context before it becomes the basis of a treatment decision.

Two Completely Different Biological Targets

Understanding why this comparison is genuinely complex requires understanding that these treatments were not designed to fight the same enemy.

Minoxidil's mechanism is vascular. It opens potassium channels in smooth muscle surrounding scalp blood vessels, causing vasodilation. More blood flow means more oxygen and growth factors delivered to the follicle bulb. The clinical effect is an extended anagen phase: follicles stay in active growth longer, which gradually thickens existing hairs and reactivates follicles in early telogen. Minoxidil does not affect DHT. It does not touch the hormone that is miniaturising the follicle from the inside. As covered in the Minoxidil vs Finasteride guide, vasodilation and DHT suppression address different problems and both are necessary for progressive androgenetic alopecia.

Peptide and botanical actives work differently across several pathways simultaneously:

Redensyl targets the outer root sheath stem cells and dermal papilla fibroblasts using stabilised polyphenols (DHQG and EGCG2). The mechanism is cellular activation, attempting to push dormant follicles back into the growth phase through biological signalling rather than vascular stimulation.

Capixyl (acetyl tetrapeptide-3 + red clover biochanin A) works on two fronts: reinforcing the extracellular matrix proteins (collagen III and laminin) that anchor the follicle, and mildly inhibiting 5-alpha reductase to reduce scalp DHT. The DHT inhibition is real, but its potency does not approach pharmaceutical Finasteride.

Procapil (oleanolic acid + apigenin + biotinoyl tripeptide-1) adds mild DHT blocking via oleanolic acid, scalp microcirculation improvement via apigenin, and structural follicle reinforcement via the peptide component.

What the RCP combination does not do is directly vasodilate. It does not powerfully block DHT the way Finasteride does. And it was never designed to. The treatments are complementary in biological design, not competing.

The Long-Term Question No 24-Week Trial Can Answer

Hair loss is not a 24-week condition. Androgenetic alopecia is a lifelong, progressive process. Evaluating long-term efficacy from a 6-month trial, conducted with subjective endpoints, on patients whose baseline Norwood stage may vary significantly, gives you a data point. It does not give you a long-term protocol.

Here is what long-term use data does tell us:

Minoxidil at 5% has been studied in trials running 12 months and longer, with standardised hair count endpoints, in populations of hundreds of patients, across multiple independent research groups. The result is consistent: it works, the effect is sustained with continued use, and it reverses within 3 to 6 months of stopping. That reversal is the most clinically important fact about Minoxidil. It is not a cure. It is maintenance.

Peptide and botanical actives do not yet have comparable long-term independent data. The Karaca and Akpolat study ran 24 weeks. No multi-year independent RCT exists for RCP with objective endpoints. This does not mean the results fade faster. It means we do not yet have the evidence to know.

What this means in practice: for a young man in Pakistan who is in his mid-20s and will be managing his hair loss for the next 40 years, the treatment that wins long-term is the one that is sustainable, tolerable, evidence-backed across the full timeline, and addresses all the active mechanisms of his specific hair loss.

A 24-week trial with subjective endpoints tells you that something happened. A 40-year hair loss timeline requires a framework, not a study.

Where the Evidence Genuinely Supports Each Approach

Minoxidil with Finasteride is the right primary framework when:

Hair loss is following a clear Norwood pattern, progressing visibly over 6 to 12 months, and affecting the crown and hairline in the characteristic distribution of androgenetic alopecia. DHT is driving the miniaturisation. Both the vasodilator (Minoxidil) and the DHT blocker (Finasteride) are needed simultaneously. The Xtra Hair range provides this at three concentration levels: Xtra Hair Topical Solution (5% Minoxidil + 0.1% Finasteride) for early stages, Xtra Hair Pro (6% Minoxidil + 0.3% Finasteride + Biotin + Caffeine) for moderate to advanced, and Xtra Hair Pro Marshal (7% Minoxidil + 0.3% Finasteride + Tretinoin + Melatonin) for Norwood III to V.

Peptide-based treatment with Regrow Xpert Actives 20% is appropriate when:

Hair loss is very early and not yet clearly androgenetic. The person cannot tolerate pharmaceutical treatment due to confirmed contraindications. Or, most commonly, they are already on pharmaceutical treatment and want to address the biological pathways that Minoxidil and Finasteride leave uncovered: stem cell activation, follicle anchoring via extracellular matrix proteins, and scalp micro-inflammation.

This last use case is the most clinically compelling for Regrow Xpert in the context of Pakistan's hair loss market. The 20% combined active concentration, significantly above the 1 to 5% total actives in most Pakistani peptide serums, means the five actives (Redensyl, Capixyl, Procapil, Anagain, Biacapil) are present at doses closer to the concentrations tested in published studies. Pairing it with pharmaceutical treatment in the morning versus evening creates a layered protocol that covers six distinct biological targets simultaneously.

How to Build a Protocol That Lasts

The question this article started with, "which wins long-term," has a more honest answer than the 2019 RCT suggests.

Neither wins in isolation for progressive androgenetic alopecia. Minoxidil without DHT suppression treats the vascular problem while the hormonal destruction continues. Peptide actives without a vasodilator and pharmaceutical DHT blocker address the edges of the problem while the centre continues to deteriorate. What wins long-term is a framework that matches the stage, addresses all active mechanisms, and remains sustainable for the duration of the condition.

That means starting with the appropriate pharmaceutical combination for your Norwood stage, which the Minoxidil 5% vs 6% vs 7% guide covers in full, and layering in peptide support once the pharmaceutical foundation is established. The how topical hair treatments improve hair density article explains the biology of what that layered approach does at the follicle level.

Frequently Asked Questions

Minoxidil ya peptide serum, konsa lena chahiye? Progressive DHT-driven hair loss ke liye Minoxidil with Finasteride primary treatment hai. Peptide serums jaise Regrow Xpert complementary layer ke tor par kaam karte hain, un biological pathways ko cover karke jo Minoxidil aur Finasteride directly address nahi karte. Dono saath long-term protocol mein sabse effective hain.

Kya Redensyl Minoxidil se better hai? 2019 Karaca and Akpolat RCT mein RCP ne 5% Minoxidil ko photographer evaluation mein outperform kiya, lekin endpoints subjective the aur Finasteride comparison mein shamil nahi tha. Objective hair count data zyada reliable hota hai. Redensyl ka long-term independent evidence abhi Minoxidil jitna mature nahi hai.

Baal girna permanently rokne ka koi tarika hai? Androgenetic alopecia mein "permanent" solution abhi tak hair transplant hi hai. Topical treatments, pharmaceutical ya botanical, maintenance karte hain jab tak use ki jaaye. Rokne ke baad 3 se 6 mahine mein regression hota hai. Consistent, long-term use hi best achievable outcome deta hai.

Kya Regrow Xpert aur Xtra Hair saath use kar sakte hain? Haan. Yahi recommended approach hai. Subah Regrow Xpert, shaam Xtra Hair. Vehicles alag waqt pe apply karna ensure karta hai ke dono properly absorb hon. Yeh protocol six different biological mechanisms simultaneously cover karta hai.

Kitne time mein fark nazar aata hai? Pharmaceutical combination therapy ke saath shedding 3 mahine mein stabilise hoti hai. Density improvement 4 se 6 mahine mein visible hoti hai. Peptide layer add karne se kuch patients earlier changes notice karte hain kyunke additional pathways cover hote hain, lekin dono ke combined results 6 se 12 mahine ke consistent use ke baad assess kiye jaate hain.

What This All Comes Down To

The 2019 RCT is real evidence. It is also incomplete evidence, measured with subjective endpoints, against pharmaceutical monotherapy, over a timeline that does not reflect the reality of a lifelong condition. Using it to dismiss Minoxidil entirely, or to justify replacing pharmaceutical treatment with a cosmetic serum, is the wrong conclusion to draw.

The right conclusion is that peptide and botanical actives address biological pathways that Minoxidil and Finasteride do not. At 20% combined concentration, Regrow Xpert Actives 20% is formulated at doses that correspond to research thresholds, not trace amounts. Used alongside the Xtra Hair range, it fills the gaps in what pharmaceutical treatment covers. That layered protocol is the most defensible long-term approach for progressive hair loss, and it is the one that Radiance360 is transparent about advocating.

Regrow Xpert Actives 20% | Xtra Hair Topical Solution | Xtra Hair Pro | Xtra Hair Pro Marshal | Hair Care Collection